Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter?

Authors / Editors

Research Areas

No matching items found.

Publication Details

Output type: Journal article

Author list: DiNicolantonio, Meier, O'Keefe

Publisher: Missouri State Medical Assoc

Publication year: 0

Volume number: 110

Issue number: 6

Start page: 495

End page: 8

Number of pages: -486

ISSN: 0026-6620

Languages: English-Great Britain (EN-GB)

Abstract

Multiple trials over the past two decades testing omega-3 polyunsaturated fatty acids (PUFAs), containing eicosapentaenoic acid (EPA) and or docosahexaenoic acid (DHA), have shown substantial benefits for reducing major coronary heart disease (CHD) events, all-cause mortality, cardiovascular (CV) death, sudden cardiac death (SCD), and stroke. However, recent trials testing omega-3s have generally failed to confirm these benefits. While increased fish and fish oil intake among the general population, increased use of optimal medical therapy (including statins, aspirin, and modern antihypertensive medications) probably make it more challenging for fish oil supplementation to show additional benefits, there might be further explanations in the formulation, dosage, and comparator used in these recent omega-3 trials.

Keywords

No matching items found.

Documents

No matching items found.